Winnersh, United Kingdom

Karine Poullennec

This inventor holds 6 USPTO granted patents. Top assignee: Vernalis &r&d) Ltd.. Active years: 2013-2021.


% Patents Active = 83.3

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 10(Granted Patents)


Location History:

  • Winnersh, GB (2013 - 2020)
  • Great Abington, GB (2021)

Company Filing History:


Years Active: 2013-2021

Loading Chart...
6 patents (USPTO):Explore Patents

Title: Karine Poullennec: Innovator in Thienopyrimidine Compounds

Introduction

Karine Poullennec is a distinguished inventor based in Winnersh, GB. She has made significant contributions to the field of pharmaceuticals, particularly in the development of thienopyrimidine compounds. With a total of 6 patents to her name, her work has garnered attention in the research and development community.

Latest Patents

Her latest patents focus on thienopyrimidine compounds, which are A receptor antagonists. These compounds are characterized by a complex formula that includes various substituents such as aryl or heteroaryl rings, and a range of alkyl and heterocyclic groups. The innovative nature of her work lies in the potential applications of these compounds in therapeutic settings.

Career Highlights

Karine is currently employed at Vernalis (R&D) Limited, where she continues to push the boundaries of pharmaceutical research. Her expertise in the synthesis and application of thienopyrimidine compounds has positioned her as a key player in her field.

Collaborations

Throughout her career, she has collaborated with notable colleagues, including Allan Michael Jordan and Simon Bedford. These partnerships have further enhanced her research capabilities and contributed to her success in the industry.

Conclusion

Karine Poullennec's innovative work in thienopyrimidine compounds exemplifies her commitment to advancing pharmaceutical research. Her contributions are paving the way for new therapeutic options and showcasing the importance of innovation in the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…